INTRODUCTION {#s1}
============

The prognosis of esophageal squamous cell carcinoma (ESCC) depends on the clinical stage of the primary tumor and the extent of lymph node metastasis (LNM) \[[@R1]\]. Lymph node status could be classified by LNM number or stations based on the latest version of the UICC/AJCC TNM classification (^8^th edition)\[[@R2]\] or Japanese Classification of Esophageal Cancer (^11^th edition)\[[@R3]\]. These two LNM classification methods define the extent of LNM by analyzing the metastatic number and range.

Serum biomarkers are biologic or biochemical substances that are produced by tumor cells, and are commonly used for identifying cancer, indicating treatment outcomes and predicting prognosis. In ESCC, it has been reported that preoperative biomarkers have a close relationship with tumor burden, including tumor invasion, LNM and the survival rate \[[@R4], [@R5]\]. But there has been no studies focusing on the correlation between biomarkers and metastatic extent of lymph node which was more valuable for clinicians to evaluate operative indication.

Squamous cell carcinoma antigen (SCC-Ag), carcinoembryonic antigen (CEA), cytokeratin 19 fragments (Cyfra21-1), carbohydrate antigen 19-9 (CA199) and carbohydrate antigen 72-4 (CA724) are commonly used in the management of esophageal cancer patients. SCC-Ag and Cyfra21-1 are sensitive biomarkers in malignant disease, particularly in squamous cell carcinoma \[[@R6], [@R7]\]. CEA, an oncofetal glycoprotein, is a representative biomarker that has been known to be elevated in almost all solid tumors, especially colorectal cancer \[[@R8]\]. In esophageal carcinoma, CEA has been reported as a diagnostic and prognostic marker \[[@R9], [@R10]\]. CA199 and CA724 are elevated in a variety of cancers, especially gastrointestinal cancer \[[@R11]--[@R13]\].

In the present study, (1) we clarify which preoperative serum levels of the biomarkers were associated with LNM status. (2) SCC-Ag, Cyrfra21-1, CEA and CA19-9, which showed a significant correlation with LNM, were selected to evaluate the relationship with lymph node metastatic number and stations. (3) We analyzed the diagnostic values of the model incorporated preoperative serum SCC-Ag, CEA and CA19-9 for lymph node metastatic extent in ESCC.

RESULTS {#s2}
=======

Patients and disease characteristics {#s2_1}
------------------------------------

In 577 ESCC patients, the median age of the patients was 61 years (range, 27 to 82 years). The median and interquartile range of SCC-Ag, Cyfra21-1, CEA, CA19-9 and CA72-4 were 0.7 ug/L (0.4-1.3 ug/L), 2.36 ug/L(1.69-3.26 ug/L), 2.19 ug/L(1.49- 3.11 ug/L), 8.66 U/ml (5.06-15.92 U/ml) and 1.30 U/ml (0.92-2.44 U/ml). Baseline patient disease characteristics are shown in Table [1](#T1){ref-type="table"}.

###### Clinical and biological characteristics of 577 patients in ESCC

  Characteristics           No. of patients (%)(N=577)
  ------------------------- ----------------------------
  Age, years                
   ≤60                      274 (47.5%)
   \> 60                    303 (52.5%)
  Sex                       
   Male                     476 (82.5%)
   Female                   101 (17.5%)
  Tumor location            
   Upper                    45 (7.8%)
   Middle                   396 (68.6%)
   Lower                    136 (23.6%)
  Pathological T status     
   T1                       21 (3.6%)
   T2                       105 (18.2%)
   T3                       235 (40.7%)
   T4a                      157 (27.2%)
   T4b                      59 (10.2%)
  Pathological N status     
   N0                       310 (53.7%)
   N1                       167 (28.9%)
   N2                       73 (12.7%)
   N3                       27 (4.7%)
  Tumor Grade               
   Grade 1                  21 (3.6%)
   Grade 2                  468 (81.1%)
   Grade 3                  88 (15.3%)
  TNM stage                 
   I                        21 (3.7%)
   IIA                      44 (7.6%)
   IIB                      180 (31.2%)
   IIIA                     139 (24.1%)
   IIIB                     33 (5.7%)
   IIIC                     160 (27.7%)
  SCC-Ag                    
   Positive (\> 1.5 ug/L)   102 (17.7%)
   Negative (≤1.5 ug/L)     463 (80.2%)
  Cyfra21-1                 
   Positive (\> 3.3 ug/L)   140 (24.3%)
   Negative (≤3.3 ug/L)     437 (75.7%)
  CEA                       
   Positive (\> 5 ug/L)     37 (6.4%)
   Negative (≤5 ug/L)       540 (93.6%)
  CA19-9                    
   Positive (\>39 U/ml)     23 (4.0%)
   Negative (≤39 U/ml)      554 (96.0%)
  CA72-4                    
   Positive (\> 6 U/ml)     46 (8.0%)
   Negative (≤6 U/ml)       531 (92.0%)

The correlations between the preoperative serum biomarkers and LNM {#s2_2}
------------------------------------------------------------------

The positive rate of serum SCC-Ag, Cyfra21-1, CEA and CA19-9 were associated with LNM in the Chi-square test (Table [2](#T2){ref-type="table"}; all *P*\<0.05). Same statistically significant results were found when assessing the relation between the biomarkers level and LNM using the Mann-Whitney-U test (SCC-Ag, *P*=0.000; Cyfra21-1, *P*=0.049; CEA, *P*=0.032; CA19-9, *P*= 0.024; CA72-2, *P*=0.361). On the multivariate analysis, SCC-Ag and CA19-9 were independent risk factors for LNM (Table [2](#T2){ref-type="table"}; *P*\<0.05).

###### Univariate and multivariate logistic regression analysis for correlation between clinical and biological characteristics and lymph node metastasis in 577 cases

  Biomarkers              Lymph node metastasis   Univariate analysis   Multivariate analysis                       
  ----------------------- ----------------------- --------------------- ----------------------- ----------- ------- -----------
  Age, years                                                                                                        
   ≤60                    140                     134                   1.267                   0.260       NA      NA
   \> 60                  169                     134                                                               
  Sex                                                                                                               
   Male                   247                     229                   3.020                   0.082       NA      NA
   Female                 62                      39                                                                
  Tumor location                                                                                                    
   Upper                  25                      20                    0.347                   0.841       NA      NA
   Middle                 214                     182                                                               
   Lower                  70                      66                                                                
  Pathological T status                                                                                             
   T1                     19                      2                     22.590                  **0.000**   \-      0.106
   T2                     66                      39                                                                
   T3                     124                     111                                                               
   T4a                    70                      87                                                                
   T4b                    30                      29                                                                
  Tumor Grade                                                                                                       
   Grade 1                17                      4                     10.810                  **0.004**           
   Grade 2                254                     214                                                       3.881   **0.019**
   Grade 3                38                      50                                                        6.096   **0.003**
  Tumor length                                                                                                      
   ≤ 3cm                  94                      43                    16.382                  **0.000**   2.198   **0.000**
   \> 3cm                 215                     225                                                               
  SCC-Ag                  263                     201                   10.138                  **0.001**   1.917   **0.005**
   Negative               40                      62                                                                
   Positive                                                                                                         
  Cyfra21-1                                                             4.566                   **0.033**   \-      0.116
   Negative               245                     192                                                               
   Positive               64                      76                                                                
  CEA                                                                   3.925                   **0.048**   \-      0.241
   Negative               295                     245                                                               
   Positive               14                      23                                                                
  CA19-9                                                                7.265                   **0.007**   3.612   **0.010**
   Negative               303                     251                                                               
   Positive               6                       17                                                                
  CA72-4                                                                2.040                   0.153       NA      NA
   Negative               289                     242                                                               
   Positive               20                      26                                                                

NA, not available (not included in multivariate analysis).

Correlations between preoperative serum biomarkers and LNM number {#s2_3}
-----------------------------------------------------------------

SCC-Ag, Cyfra21-1, CEA and CA19-9 were chosen to analyze the correlations with pN stage. The positive rate of serum SCC-Ag and CA19-9 were associated with pN stage (Table [3](#T3){ref-type="table"}; *P*=0.010 and *P*=0.004). To further examine the relationship between SCC-Ag, Cyfra21-1, CEA and CA19-9 and the LNM extent, patients with pN0 and pN1were selected (477 patients in total). In this subpopulation, the positive rate of SCC-Ag was much higher in pN1 stage patients compared to those in pN0 stage patients (23.9% vs. 13.2%, *P*=0.003), but no correlations were found in Cyfra21-1, CEA and CA19-9 (all *P*\>0.05). (Table [4](#T4){ref-type="table"}).

###### Correlation between biomarkers and pN stage in 577 ESCC patients

  pN stage   SCC-Ag   *P* value   Cyfra21-1   *P* value   CEA   *P* value   CA19-9   *P* value                     
  ---------- -------- ----------- ----------- ----------- ----- ----------- -------- ----------- ------- ----- --- -------
  N0         263      40          0.010       246         64    0.065       296      14          0.137   306   6   0.004
  N1         124      39                      122         45                155      12                  161   6   
  N2         57       15                      53          20                67       8                   66    7   
  N3         19       8                       16          11                24       3                   23    4   

###### Correlation between biomarkers and early stage lymph node metastasis in 477 pN0-1 stage patients

  pN stage   SCC-Ag   *P* value   Cyfra21-1   *P* value   CEA   *P* value   CA19-9   *P* value                     
  ---------- -------- ----------- ----------- ----------- ----- ----------- -------- ----------- ------- ----- --- -------
  N0         263      40          0.003       246         64    0.118       296      14          0.221   304   6   0.270
  N1         124      39                      122         45                155      12                  161   6   

For analyzing the advanced stage of LNM, patients were divided into two subgroups, pN0-1 and pN2-3. Patients with pN0-1stage were considered earlier and less extensive LNM, while patients with pN2-3 stage were considered more extensive LNM. High positive rate of preoperative serum CEA and CA199 were associated with more extensive LNM (*P*=0.039, *P*=0.000, respectively). However, no correlation was found in SCC-Ag (P=0.105) (Table [5](#T5){ref-type="table"}).

###### Correlation between biomarkers and advanced stage lymph node metastasis in 577 ESCC patients

  Tumor markers   N0-1(LNM≤2)   N2-3(LNM\>2)   χ^2^     *P* value
  --------------- ------------- -------------- -------- -----------
  SCC-Ag                                                
   Negative       387           76             2.176    0.140
   Positive       79            23                      
  Cyfra21-1                                    2.987    0.084
   Negative       368           69                      
   Positive       109           31                      
  CEA                                          4.242    **0.039**
   Negative       451           89                      
   Positive       26            11                      
  CA19-9                                       15.548   **0.000**
   Negative       465           89                      
   Positive       12            11                      

Correlations between preoperative serum biomarkers and LNM groups {#s2_4}
-----------------------------------------------------------------

Japanese Classification of Esophageal Cancer (11th edition) \[[@R3]\] graded pN stage(JES) based on the LNM groups which were defined according to the location of the tumor. For middle thoracic ESCC, middle thoracic paraesophageal lymph nodes and paracardial lymph nodes were involved in pN1 (JES), subcarinal lymph nodes and left gastric artery lymph nodes were involved into pN2 (JES). pN2 (JES) stage was more extensive lymphatic invasion than pN1 (JES) stage.

In middle thoracic ESCC, the positive rate of SCC-Ag was correlated with paraesophageal and paracardial lymph nodes in pN1 (JES) (all *P*\<0.05), but not correlated with subcarinal and left gastric artery lymph nodes in pN2 (JES). Interestingly, the association between the positive rate of CEA and LNM groups were opposite to that in SCC-Ag. Significant results of CEA were found in pN2 group (JES) (all *P*\<0.05) and not in pN1 group (JES). The positive rate of serum CA19-9 was associated with subcarinal and paracardial LNM (*P*=0.000, *P*=0.038) (Table [6](#T6){ref-type="table"}).

###### Correlation between biomarkers and lymph node metastatic groups in 396 middle thoracic ESCC

  Tumor marker                                 SCC-Ag   *P* value   CEA         *P* value   CA19-9   *P* value              
  -------------------------------------------- -------- ----------- ----------- ----------- -------- ----------- ----- ---- -----------
  middle thoracic paraesophageal lymph nodes                        **0.012**                        0.963                  0.559
   Negative                                    267      51                      301         23                   311   13   
   Positive                                    49       20                      67          5                    68    4    
  paracardial lymph nodes                                                                                                   
   Negative                                    284      52          **0.000**   322         23       0.415       333   12   **0.038**
   Positive                                    32       19                      46          5                    46    5    
  subcarinal lymph nodes                                                                                                    
   Negative                                    281      59          0.174       327         21       **0.030**   338   10   **0.000**
   Positive                                    35       12                      41          7                    41    7    
  left gastric artery lymph nodes                                                                                           
   Negative                                    265      53          0.067       307         19       **0.037**   314   12   0.195
   Positive                                    51       18                      61          9                    65    5    

A biomarkers diagnostic model and risk groups to LNM {#s2_5}
----------------------------------------------------

To better identify ESCC patients at high risk for LNM, we proposed a new diagnostic model by combining SCC-Ag, CEA and CA19-9, and stratified patients into four groups. Grade 1 group: negative SCC-Ag, CEA and CA19-9; Grade 2 group: positive SCC-Ag, negative CEA and negative CA19-9; Grade 3 group: negative SCC-Ag with positive CEA or positive CA19-9 or both; Grade 4 group: positive SCC-Ag with positive CEA or positive CA19-9 or both. In the patients reported here, there are 422, 91, 41 and 11 patients in the grade 1, 2, 3 and 4 groups, respectively. With this model, the analysis showed the rate of patients with pN2-3 stage in ESCC was 15.4% in grade 1 group. The rate of LNM patients was 81.8% and the rate of patients with pN2 -3 stage was 54.5% in grade 4 group. ROC curve analyses were performed, the area under the ROC curve (AUC) in predicting LNM with this model was 0.567 (*P*=0.006). The AUC in predicting LNM extent with this model was 0.563 (*P*=0.048) ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}) (Table [7](#T7){ref-type="table"}).

###### The discriminatory value of diagnostic model for lymph node metastatic extent in 577 ESCC patients

  Diagnostic model   Lymph node metastasis   χ^2^         *P* value    Lymph node metastasis extent   χ^2^         *P* value            
  ------------------ ----------------------- ------------ ------------ ------------------------------ ------------ ----------- -------- -----------
  Grade 1 group      244(57.8%)              178(42.2%)   15.240       **0.002**                      357(84.6%)   65(15.4%)   14.287   **0.003**
  Grade 2 group      38(41.8%)               53(58.2%)    74 (81.3%)   17(18.7%)                                                        
  Grade 3 group      18(43.9%)               23(56.1%)    30(73.2%)    11(26.8%)                                                        
  Grade 4 group      2(18.2%)                9 (81.8%)    5 (45.5%)    6(54.5%)                                                         

DISCUSSION {#s3}
==========

To our knowledge, our report is the largest published retrospective study to date that analyzes the correlation between preoperative serum biomarkers (SCC-Ag, Cyfra21-1, CEA, CA19-9 and CA72-4) and LNM in ESCC. More importantly, there have been no studies investigating the predictive values of these preoperative serum biomarkers to the extent of LNM. The present study found that the serum SCC-Ag, CEA and CA19-9 were closely associated with lymph node metastatic extent. Different serum biomarkers revealed different stages of LNM. The model we built will help predict LNM and further define the precise status of pN stage (N0-1 or N2-3).

ESCC has a high prevalence in Asia and easily metastasizes to lymph nodes. Neoadjuvant therapy, especially preoperative chemoradiation therapy, could downstage the tumor, significantly reduce the 3-year mortality and locoregional recurrence compared with surgery alone \[[@R15]--[@R17]\]. The clinical value of preoperative lymph node status identification is to decide whether patients should undergo neoadjuvant therapy first. Diagnostic imaging techniques, including computed tomography and endosonography, have limitation that cannot predict lymph node status sufficiently. Preoperative serum biomarkers, which are measured routinely prior to treatment, could provide information of LNM based on our study presented here.

SCC-Ag and Cyfra21-1 are sensitive biomarker in malignant disease, particularly in squamous carcinoma \[[@R6], [@R7]\]. In ESCC, the positive rate of SCC-Ag and Cyfra21-1 previously reported were 25.2% - 38% \[[@R4], [@R18]--[@R20]\] and 17.7%- 47.8% \[[@R5], [@R20]\]. In our study, the positive rate of SCC-Ag and Cyfra21-1 were 18.1% and 24.3%. Different positive rates of these biomarkers might result from different proportion of TNM stage and detected method. Previous studies have indicated that SCC-Ag was correlated with LNM in head and neck, cervical, penile and anal canal cancer \[[@R21]--[@R24]\]. In esophageal cancer, except LNM, elevated SCC-Ag was also associated with tumor size, depth of tumor invasion, TNM stage and poor survival rate \[[@R4], [@R5], [@R25]\]. Similar results were observed in this study and SCC-Ag was an independent risk factor for LNM. We also examined SCC-Ag in pN0-1 stage patients (LNM number ≤ 2) which could analyze early stage lymph node metastatic status. In this subgroup, only SCC-Ag was associated with LNM (*P*=0.003) and its specificity was 86.8%. Although Cyfra21-1, CEA and CA19-9 were associated with LNM in ESCC, they do not serve as precise predictors for early stage LNM.

There is a controversy for categorizing pathological N stage based on UICC/AJCC TNM classification or Japanese Classification of Esophageal Cancer. These two methods represent different aspects of LNM extent. Larger number or range of LNM stands for more extensive metastasis and later stage. Among the 4 biomarkers, only high positive rate of CEA and CA19-9 were demonstrated to associate with advanced stage LNM. There was no significant difference for SCC-Ag (*P*=0.140). These results showed SCC-Ag would be elevated at early stage of LNM and could predict early LNM status. On the contrary, CEA and CA19-9 could predict advanced LNM status.

It should be noted that our purpose to analyze the correlation between lymph node stations and biomarkers was not to predict the specific lymph node station metastatic status with markers. In Japanese Classification of Esophageal Cancer, some specific lymph node stations stand for more extensive metastasis. To confirm our thoughts above, we chose middle thoracic esophageal carcinoma patients and analyzed the status of middle thoracic paraesophageal lymph nodes (pN1, JES) and paracardial lymph nodes (pN1, JES), subcarinal lymph nodes (pN2, JES), and left gastric artery lymph nodes (pN2, JES). Interestingly, SCC-Ag was significantly associated with pN1 (JES) stage LNM (*P*\<0.05), but not pN2 (JES) stage (*P*\>0.05). Opposite relationships with lymph node stations were found in CEA. Similar results of CA19-9 were verified in the thoracic lymph node stations. In abdominal lymph node stations, CA19-9 was correlated with paracardial LNM. A probable reason for this discrepancy may be explained as follows. Wang et al. \[[@R26]\]argued that most patients had abdominal LNM accompanied by thoracic (mediastinal) LNM at the same time and the 5-year survival rate was lower than that of patients with thoracic LNM. CA19-9 could not indentify well in abdominal LNM whose lymph metastasis extent was more severe compared with thoracic LNM.

The positive rate of CEA in ESCC ranges from 9.1% to 23% \[[@R4], [@R18], [@R27]\]. CEA has been reported to own the function of an adhesion molecule. CEA- containing tumor cells could preferentially go into metastatic cascade \[[@R28], [@R29]\]. Kosugi et al.\[[@R4]\] reported that CEA had no correlation with LNM, but with distant metastasis in ESCC. However, another study revealed significant differences were found between CEA and LNM in ESCC \[[@R18]\]. CA19-9 is also called sialylated Lewis Antigen which is speculated to play roles in the extravasation of cancer cells from blood and the promotion of metastatic spread to distant organs \[[@R30]\]. CA19-9 was widely used in pancreatic cancer, colon cancer, gastric cancer, and other gastrointestinal tumors \[[@R11], [@R12], [@R31]--[@R33]\]. In a meta-analysis of gastric cancer, there were the correlation between elevated CA19-9 and LNM, T stage, TNM stage, vessel invasion and poor survival rate \[[@R34]\]. In ESCC, Zhao et al. \[[@R31]\] first reported CA19-9 with a new cutoff value was associated with LNM and hematogenic metastasis. Our study reveals that elevated CEA and CA19-9 are associated with advanced stage of LNM.

Together with previous findings, our study provided a LNM predictive model, which could help identify the extent of LNM. Patients with advanced stage LNM, which was classified into III stage or above (based on UICC/AJCC TNM classification), are recommended to undergo preoperative chemoradiotherapy or chemotherapy first.

Several limitations to our study exist. Since the analyses were performed retrospectively on a single institutional database, selection biases might be underestimated. Additional validation of the models using different data sets might further prove the clinical value of the model.

In conclusion, this study demonstrates the correlation between LNM and the positive rate of preoperative serum SCC-Ag, Cyfra21-1, CEA and CA19-9. SCC-Ag was associated with early lymph node metastatic stage. CEA and CA19-9 have a close relationship with advanced lymph node metastatic stage. The model incorporated SCC-Ag, CEA and CA19-9 could further increase the predictive value for the LNM status of esophageal squamous cell carcinoma.

MATERIALS AND METHODS {#s4}
=====================

Patients and eligibility criteria {#s4_1}
---------------------------------

Among patients with esophageal squamous cell carcinoma undergone esophagectomy in Cancer Institute and Hospital of Tianjin Medical University from January 2007 to December 2010, the study was conducted on 577 patients whose preoperative serum SCC-Ag, Cyfra21-1, CEA, CA19-9 and CA72-4 were examined. The cases exclude from the current study based on the following criteria: (1) patients who had history of malignant disease; (2) patients who had received preoperative treatment (chemotherapy and/or radiotherapy); (3) patients who had other malignant tumors except esophageal squamous carcinoma.

The serum Cyfra21-1, CEA, CA19-9 and CA72-4 were detected within 7 days before surgery with electrochemiluminescence immunoassay (Roche Elecsys E170, Germany). The SCC-Ag was detected by chemical luminescence immunoassay (Abbott Architect i2000, America). The normal upper limit was 1.5 ug/L, 3.3 ug/L, 5 ug/L, 39 U/ml and 6 U/ml for SCC-Ag, Cyfra21-1, CEA, CA19-9 and CA72-4 respectively. The esophagectomy with 2- to 3- field lymph node dissection was taken for standard treatment. The depth of primary tumor, degree of lymph node (pN stage) and TNM staging were defined according to UICC/AJCC TNM classification (7th edition)\[[@R14]\]. For analyzing the relationship between lymph node metastatic range and biomarkers, the LNM grading method of Japanese Classification of Esophageal Cancer (11th edition) \[[@R3]\] also were used and defined as "pN stage (JES)". JES is the abbreviation for Japanese Esophageal Society. In present study, we defined pN1 and pN2-3 (UICC/AJCC TNM classification or Japanese Classification of Esophageal Cancer) as early stage and advanced stage LNM to analyze the correlation between biomarkers and LNM extent.

Statistical analysis {#s4_2}
--------------------

The statistical analyses were performed with the SPSS 21.0 software (ver. 21 SPSS Inc., Chicago, IL). The correlations between serum level of biomarkers and clinicopathological characteristics were assessed using the Chi-square or Mann-Whitney-U test. Significant risk factors identified by univariate analysis were further assessed by multivariate analysis using logistic regression. A receiver operating characteristic (ROC) curve was constructed. *P* \< 0.05 was considered statistically significant.

SUPPLEMENTARY MATERIALS FIGURE {#s5}
==============================
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